EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Time for optimism in amyotrophic lateral sclerosis

Philippe Corcia iD, Christian Lunetta, Patrick Vourc'h, Pierre-François Pradat, Hélène Blasco

European Journal of Neurology · 2023-05 · 30 (5) · 1459-1464

DOI: 10.1111/ene.15738 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Neurology, online erschienen am 23.02.2023. Verfasst von Philippe Corcia und 4 weiteren Autor:innen. Beteiligte Einrichtung: CRMR SLA, CHU Tours, Tours, France. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Motor Neuron Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Amyotrophic lateral sclerosis (ALS) is among the most common motor neuron diseases in adults. Nevertheless, ALS remains fatal, despite decades of research and clinical trials, which has led to negative conclusions until recently in regard to four specific treatments. It is well known that we can learn from failures, and we consider that the time has come to present positive insight on this disease.

Methods

We did a literature search using PubMed and Scopus for articles published in English from 1 January 2016, to 30 June 2022 dealing with “amyotrophic lateral sclerosis”, diagnosis, treatment, and biomarkers.

Results

A comprehensive review of the literature on diagnosis, monitoring, and treatment of this condition showed convincing evidence that we are now able to diagnose earlier as well as to better monitor and treat ALS.

Conclusions

Although ALS is often difficult to diagnose and remains incurable, there are many indications that an optimistic view of ALS management in the coming years is now realistic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisMotor Neuron DiseaseAdultHumansBiomarkers

Stichwörter der Autor:innen

SOD1-C9orf72amyotrophic lateral sclerosisgeneticsneurofilaments

Substanzen

Biomarkers

Autor:innen und Institutionen

  • CRMR SLA, CHU Tours, Tours, France.
  • UMR1253 iBrain UMR, Université de Tours, INSERM, Tours, France.
  • ALS Unit, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy.
  • Laboratoire de Biochimie et Biologie Moléculaire, CHRU de Tours, Tours, France.
  • CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Sorbonne Université, Paris, France.
  • Département de Neurologie, Hôpital Pitié-Salpêtrière, Centre référent SLA, APHP, Paris, France.

ORCID-Profile: Philippe Corcia

Zitieren

APA

Corcia, P., Lunetta, C., Vourc'h, P., Pradat, P. F., & Blasco, H. (2023). Time for optimism in amyotrophic lateral sclerosis. European Journal of Neurology, 30(5), 1459-1464. https://doi.org/10.1111/ene.15738

Vancouver

Corcia P, Lunetta C, Vourc'h P, Pradat PF, Blasco H. Time for optimism in amyotrophic lateral sclerosis. European Journal of Neurology. 2023;30(5):1459-1464. doi:10.1111/ene.15738

BibTeX
@article{Corcia2023,
  author = {Corcia, Philippe and Lunetta, Christian and Vourc'h, Patrick and Pradat, Pierre-François and Blasco, Hélène},
  title = {Time for optimism in amyotrophic lateral sclerosis},
  journal = {European Journal of Neurology},
  year = {2023},
  volume = {30},
  number = {5},
  pages = {1459--1464},
  doi = {10.1111/ene.15738}
}
Kostenlos starten →